| Assessment Status | Rapid review complete |
| HTA ID | 22040 |
| Drug | Dapagliflozin |
| Brand | Forxiga® |
| Indication | For the treatment of chronic kidney disease |
| Assessment Process | |
| Rapid review commissioned | 08/06/2022 |
| Rapid review completed | 14/07/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that dapaglifozin not be considered for reimbursement at the submitted price.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
